Today’s FY results highlight continued robust growth with services revenue +30% YoY (+27% excl. acquisitions), propelled as expected by Drug Safety and Medical Information (+63%), and adj. EBITDA ahead of our forecasts. The company’s backlog of contracted revenue has expanded further to £70m (from £59m last year), providing a high level of revenue visibility. Following the release in February 2017 of positive Phase II data on lorediplon (insomnia) by co-development partner Ferrer, we continue to ....
28 Mar 2017
N+1 Singer - Ergomed - FY results show strong Services growth; Phase III Zoptrex® data ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - FY results show strong Services growth; Phase III Zoptrex® data ahead
- Published:
28 Mar 2017 -
Author:
Sheena Berry -
Pages:
3
Today’s FY results highlight continued robust growth with services revenue +30% YoY (+27% excl. acquisitions), propelled as expected by Drug Safety and Medical Information (+63%), and adj. EBITDA ahead of our forecasts. The company’s backlog of contracted revenue has expanded further to £70m (from £59m last year), providing a high level of revenue visibility. Following the release in February 2017 of positive Phase II data on lorediplon (insomnia) by co-development partner Ferrer, we continue to ....